Second, whenever feasible, molecular profiling of the tumour (including assessment for somatic NF1 and other RAS-pathway alterations) can provide etiologic insight and may, in future, help identify targeted therapeutic opportunities for unresectable or metastatic disease. This evidence concerns the gene NF1 and neoplasm.